Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Impedimed Limited ( (AU:IPD) ).
Impedimed Limited announced a change in the director’s interest notice, specifically regarding Ms. Christine Emmanuel-Donnelly’s holdings. The change involved an acquisition of 306,446 ordinary shares in the Donnelly Superannuation Fund, increasing her total holdings in this fund to 1,736,255 shares. This transaction, conducted as an on-market trade, reflects the director’s increased investment in the company, potentially signaling confidence in Impedimed’s future prospects and stability.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
Impedimed Limited operates in the medical technology industry, focusing on products that provide non-invasive solutions for measuring, monitoring, and managing fluid status and tissue composition. The company primarily serves healthcare providers and patients, aiming to improve clinical outcomes through its innovative technologies.
Average Trading Volume: 1,423,122
Technical Sentiment Signal: Sell
Current Market Cap: A$60.82M
Find detailed analytics on IPD stock on TipRanks’ Stock Analysis page.